cardonilizumab combined with renvastinib
2024-HS-091
Phase 2 small_molecule active
Quick answer
cardonilizumab combined with renvastinib for Resectable Clear Cell Carcinoma of the Kidney is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Resectable Clear Cell Carcinoma of the Kidney
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active